Current and emerging therapies for PNETs in patients with or without MEN1
Pancreatic neuroendocrine tumours (PNETs) might occur as a non-familial isolated endocrinopathy or as part of a complex hereditary syndrome, such as multiple endocrine neoplasia type 1 (MEN1). MEN1 is an autosomal dominant disorder characterized by the combined occurrence of PNETs with tumours of th...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Published: |
Nature Publishing Group
2018
|
| _version_ | 1797090725442093056 |
|---|---|
| author | Frost, M Lines, K Thakker, R |
| author_facet | Frost, M Lines, K Thakker, R |
| author_sort | Frost, M |
| collection | OXFORD |
| description | Pancreatic neuroendocrine tumours (PNETs) might occur as a non-familial isolated endocrinopathy or as part of a complex hereditary syndrome, such as multiple endocrine neoplasia type 1 (MEN1). MEN1 is an autosomal dominant disorder characterized by the combined occurrence of PNETs with tumours of the parathyroids and anterior pituitary. Treatments for primary PNETs include surgery. Treatments for non-resectable PNETs and metastases include biotherapy (for example, somatostatin analogues, inhibitors of receptors and monoclonal antibodies), chemotherapy and radiological therapy. All these treatments are effective for PNETs in patients without MEN1; however, there is a scarcity of clinical trials reporting the efficacy of the same treatments of PNETs in patients with MEN1. Treatment of PNETs in patients with MEN1 is challenging owing to the concomitant development of other tumours, which might have metastasized. In recent years, preclinical studies have identified potential new therapeutic targets for treating MEN1-associated neuroendocrine tumours (including PNETs), and these include epigenetic modification, the β-catenin–wingless (WNT) pathway, Hedgehog signalling, somatostatin receptors and MEN1 gene replacement therapy. This Review discusses these advances. |
| first_indexed | 2024-03-07T03:22:49Z |
| format | Journal article |
| id | oxford-uuid:b80217c5-153e-4991-8d8e-edc02af83faf |
| institution | University of Oxford |
| last_indexed | 2024-03-07T03:22:49Z |
| publishDate | 2018 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:b80217c5-153e-4991-8d8e-edc02af83faf2022-03-27T04:52:54ZCurrent and emerging therapies for PNETs in patients with or without MEN1Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b80217c5-153e-4991-8d8e-edc02af83fafSymplectic Elements at OxfordNature Publishing Group2018Frost, MLines, KThakker, RPancreatic neuroendocrine tumours (PNETs) might occur as a non-familial isolated endocrinopathy or as part of a complex hereditary syndrome, such as multiple endocrine neoplasia type 1 (MEN1). MEN1 is an autosomal dominant disorder characterized by the combined occurrence of PNETs with tumours of the parathyroids and anterior pituitary. Treatments for primary PNETs include surgery. Treatments for non-resectable PNETs and metastases include biotherapy (for example, somatostatin analogues, inhibitors of receptors and monoclonal antibodies), chemotherapy and radiological therapy. All these treatments are effective for PNETs in patients without MEN1; however, there is a scarcity of clinical trials reporting the efficacy of the same treatments of PNETs in patients with MEN1. Treatment of PNETs in patients with MEN1 is challenging owing to the concomitant development of other tumours, which might have metastasized. In recent years, preclinical studies have identified potential new therapeutic targets for treating MEN1-associated neuroendocrine tumours (including PNETs), and these include epigenetic modification, the β-catenin–wingless (WNT) pathway, Hedgehog signalling, somatostatin receptors and MEN1 gene replacement therapy. This Review discusses these advances. |
| spellingShingle | Frost, M Lines, K Thakker, R Current and emerging therapies for PNETs in patients with or without MEN1 |
| title | Current and emerging therapies for PNETs in patients with or without MEN1 |
| title_full | Current and emerging therapies for PNETs in patients with or without MEN1 |
| title_fullStr | Current and emerging therapies for PNETs in patients with or without MEN1 |
| title_full_unstemmed | Current and emerging therapies for PNETs in patients with or without MEN1 |
| title_short | Current and emerging therapies for PNETs in patients with or without MEN1 |
| title_sort | current and emerging therapies for pnets in patients with or without men1 |
| work_keys_str_mv | AT frostm currentandemergingtherapiesforpnetsinpatientswithorwithoutmen1 AT linesk currentandemergingtherapiesforpnetsinpatientswithorwithoutmen1 AT thakkerr currentandemergingtherapiesforpnetsinpatientswithorwithoutmen1 |